Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study - Université de Versailles Saint-Quentin-en-Yvelines Access content directly
Journal Articles Autoimmunity Reviews Year : 2024

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study

Virginia Solitano
  • Function : Author
Paola Facheris
  • Function : Author
Magnus Petersen
  • Function : Author
Ferdinando d'Amico
  • Function : Author
Michela Ortoncelli
  • Function : Author
Daniel Aletaha
  • Function : Author
Pablo Olivera
  • Function : Author
Thomas Bieber
  • Function : Author
Sofia Ramiro
  • Function : Author
Subrata Ghosh
  • Function : Author
Britta Siegmund
  • Function : Author
Isabelle Chary-Valckenaere
  • Function : Author
Ailsa Hart
  • Function : Author
Lorenzo Dagna
  • Function : Author
Fernando Magro
  • Function : Author
Renaud Felten
  • Function : Author
Paulo Gustavo Kotze
  • Function : Author
Vipul Jairath
  • Function : Author
Antonio Costanzo
  • Function : Author
Lars Erik Kristensen
  • Function : Author
Laurent Peyrin Biroulet
  • Function : Author
Silvio Danese
  • Function : Author

Domains

Health
No file

Dates and versions

hal-04551288 , version 1 (18-04-2024)

Identifiers

Cite

Virginia Solitano, Paola Facheris, Magnus Petersen, Ferdinando d'Amico, Michela Ortoncelli, et al.. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study. Autoimmunity Reviews, 2024, 23 (3), pp.103504. ⟨10.1016/j.autrev.2023.103504⟩. ⟨hal-04551288⟩
3 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More